Vigil Neuroscience, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
Beryl Capital Management and its affiliates have fully divested their beneficial ownership in Vigil Neuroscience, Inc., reporting 0% ownership.
Biotechnology Value Fund and its affiliates have fully divested their beneficial ownership in Vigil Neuroscience, Inc. as of June 30, 2025.
Glazer Capital, LLC and Paul J. Glazer report beneficial ownership of 6.45% of Vigil Neuroscience, Inc.'s common stock.
Glazer Capital, LLC and Paul J. Glazer have reported a 5.39% beneficial ownership stake in Vigil Neuroscience, Inc. common stock, held for investment purposes.
Beryl Capital Management and its affiliates have disclosed a significant beneficial ownership stake of 9.9% in Vigil Neuroscience, Inc., totaling 4,606,267 shares of common stock.
A group of investment entities led by Biotechnology Value Fund and Mark N. Lampert has filed an amended Schedule 13G, disclosing a combined beneficial ownership of 9.99% in Vigil Neuroscience, Inc. as of March 31, 2025.
SCHEDULE 13G/A: Invus Entities and Raymond Debbane Disclose Passive Stake in Vigil Neuroscience, Inc. Below 5%
Multiple Invus-affiliated entities and Raymond Debbane have filed an amended Schedule 13G, disclosing beneficial ownership of Vigil Neuroscience, Inc. Common Stock, with Raymond Debbane holding 4.9% as of December 31, 2024.